CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, has a couple of clinical trial events to watch in the coming months.
The lead compound is Auxora, a potent and selective small molecule calcium release activated calcium (CRAC) channel inhibitor. CRAC channels may become hyperactive in specific tissues as a consequence of infection, trauma, or exposure to toxins, leading to cellular damage and death, contributing to a range of diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com